Last updated on February 2017

Use of Biosimilar Nivestim to Prevent Chemo-induced Neutropenia. Real Life Study


Brief description of study

The aim of this study is to describe in real-life conditions the determinants of use of GCSF (Granulocyte Colony-Stimulating Factor) Nivestim® in primary or secondary prophylaxis and in patients receiving chemotherapy for solid tumour according to the chemotherapy context: adjuvant or metastatic setting.

Detailed Study Description

This is a longitudinal, observational, prospective, multicentre, cohort study, conducted in France among a representative sample of public and/or private hospital-based oncologists. Data will be collected by the investigator during three visits using data available in the patient medical record and obtained from patient questioning and clinical examination performed during the consultations: - Baseline visit: prescription of Nivestim®. - Follow-up visit: during the first cycle of chemotherapy after the first course of Nivestim®. - Final visit: after the last cycle of chemotherapy or 16-18 weeks after inclusion.

Clinical Study Identifier: NCT02454530

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Centre de Radioth rapie Hartmann
Levallois Perret, France
  Connect »

Pfizer CT.gov Call Center

Institut Franco Britannique Service Oncologie M dicale
Levallois Perret, France
  Connect »

Pfizer CT.gov Call Center

Clinique Hartmann Service Oncologie
Levallois Perret Cedex, France
0.33miles
  Connect »

Pfizer CT.gov Call Center

Institut Mutualiste Montsouris Service Oncologie M dicale
Paris, France
4.6miles
  Connect »

Pfizer CT.gov Call Center

H pital Avicenne Service Gastro-Ent rologie
Bobigny Cedex, France
5.95miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.